Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended January 31, 1996, for Primedex Health Systems, Inc. (the Registrant). The Registrant's primary continuing operations are conducted through its subsidiary, Radnet, Inc., a radiology management services organization. During the quarter, the company also integrated Future Diagnostics, Inc. (FDI), acquired in November 1995. The company has discontinued operations related to its former Primedex Corporation subsidiary and CareAdvantage, Inc.
Key Financial Metrics
| Metric | Q1 1996 | Q1 1995 |
|---|---|---|
| Net Revenue | $13,839,451 | $11,726,575 |
| Operating Income | $984,294 | $(2,222,301) |
| Net Loss | $(163,944) | $(3,236,297) |
| Cash and Equivalents (End of Period) | $1,333,286 | $3,105,452 |
| Working Capital | $(8,356,133) | $(1,362,144) |
| Total Debt (Current + Long-Term) | $76,629,724 | N/A |
Note: Total Debt calculated as sum of Notes/Leases Payable (Current & Long-Term) and Subordinated Debentures.
Material Changes vs. Prior Period
- Profitability Improvement: The company shifted from an operating loss of $2.22 million in Q1 1995 to an operating income of $984,294 in Q1 1996. This was driven by a significant reduction in depreciation and amortization expenses (from $2.15M to $1.17M) following a goodwill impairment write-off in the prior fiscal year.
- Revenue Growth: Net revenue increased by approximately 18% year-over-year, aided by the inclusion of FDI revenues ($1.9M) and stable performance from Radnet.
- Liquidity Deterioration: Cash and cash equivalents decreased by $2.6 million during the quarter. Working capital deficit widened significantly to $8.36 million, primarily due to the reclassification of $5.2 million in notes payable to current liabilities (suspended payments) and the assumption of liabilities from the FDI acquisition.
- Extraordinary Gain: The company recorded a $181,350 gain from the early extinguishment of debt, partially offsetting the net loss.
Outlook, Risks, and Contingencies
- Legal Settlement: The company settled a securities class action lawsuit ("In re Hibbard Brown & Company") by agreeing to pay $240,000 into an escrow fund. The settlement is pending court and class member approval.
- Regulatory Investigation: The Los Angeles District Attorney confirmed it is not investigating current management or present business activities. The investigation remains focused on former management of the defunct Primedex Corporation subsidiary.
- Lease Litigation: Radnet faces lawsuits from lessors of closed imaging centers regarding past due rent and damages. The company has accrued $1.25 million for these costs, with no assurance of final settlement amounts.
- Debt Obligations: Significant debt service is required. Radnet has approximately $24.4 million in debt and lease payments due in the next year. The company relies on lines of credit secured by accounts receivable to meet working capital needs.
- Capital Expenditures: The company is committed to spending at least $1.25 million over the next year to develop a centralized scheduling and billing system, largely financed by equipment suppliers.
Investor Verification Checklist
- Verify the status of the $240,000 class action settlement and whether it has received final court approval.
- Confirm the company's ability to service its $24.4 million in near-term debt obligations given the current working capital deficit.
- Monitor the outcome of lease litigation regarding closed Radnet centers and potential increases to the $1.25 million accrual.
- Assess the integration progress and revenue contribution of the Future Diagnostics, Inc. (FDI) acquisition.
- Review the terms of the suspended $5.2 million debt payments and the status of negotiations with the lender.